Masteron Propionate
Drostanolone Prop · Mast P
DHT-derived drostanolone propionate; anti-estrogenic, cutting agent. Simple model — peak calibrated.
Overview
Masteron (drostanolone propionate) is an injectable DHT derivative carrying a C17beta propionate ester, originally developed clinically (as Drolban) for breast cancer before being displaced by tamoxifen. It binds the androgen receptor, does not aromatize, and is not further 5-alpha-reduced, which is why it earned a reputation as an anti-estrogenic cutting agent (it competes weakly at the aromatase and estrogen receptor level). Its 2-day half-life (48 hours) requires every-other-day injection to keep serum levels flat in research protocols. Hepatotoxicity is rated none, the side-effect profile is comparatively mild, and the primary harm-reduction concerns are androgenic (hair, skin, prostate in susceptible users) plus HPTA suppression, which is dose- and duration-dependent. Because it is a pure DHT derivative with no estrogenic conversion, it is typically stacked rather than run alone.
Pharmacokinetic summary
- Model tier
- Simple (t½ + F, Tmax estimated)
- Half-life
- 2 days
- Cmax
- 71.3 ng/dL
- Bioavailability
- 84%
- Typical dose
- 50–150 mg
Harm reduction
- Aromatizes
- No
- DHT derivative
- Yes
- Injection frequency
- EOD
Related compounds
Masteron Enanthate
Longer-acting drostanolone ester. Simple model — peak calibrated.
Testosterone Enanthate
Long-acting testosterone ester; the most common TRT and cycle base. Reaches steady state in ~5 weeks.
Testosterone Cypionate
Standard US TRT ester with a slightly longer release tail than enanthate. Steady state ~4–5 weeks.
Comments
Loading comments…